AC Immune SA stock is up 6.67% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 7 November’s closed higher than October. In the last 1 Unusual Options Trades, there were 1 PUT. 100% of analysts rate it a buy.
AC Immune SA discovers, designs, and develops medicines and diagnostic products. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease. It is also developing ACI-24, an anti-Abeta vaccine candidate, as well as completed Phase Ib clinical study for Down syndrome. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases.